Application of antisense oligonucleotide in preparation of medicine for treating breast cancer
By designing a specific sequence of all thio antisense oligonucleotide S-ASODN-1 to target IGF1R, the problem of lack of IGF1R target drugs in the prior art was solved, and significant inhibition of breast cancer cells and effective tumor growth was achieved. control.
Patent Information
- Application Number
- CN202310553403.8
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2023-05-16
- Publication Date
- 2024-11-22
AI Technical Summary
The existing breast cancer treatment methods lack drugs targeting the insulin-like growth factor-1 receptor IGF1R, and the inhibitory activity of antisense oligonucleotides on breast cancer cells is quite different, making it difficult to effectively inhibit breast cancer. Cell proliferation and tumor growth.
Design and synthesize all thio antisense oligonucleotide S-ASODN-1 with specific sequences to target IGF1R, select target sequences by aligning with GeneBank online blast sequences to ensure specificity and perform all thio Modification to prolong the time of action in the body and synthesized by solid phase method.
S-ASODN-1 significantly inhibited the proliferation of human breast cancer cell lines MCF7, BT474 and T47D, with an inhibition rate of 52.32% to 70.76%, and it was dose-dependent and had a sustained effect. The inhibition effect of the medium and high dose group was better than that of the positive control sorafinib. , significantly inhibits breast cancer tumor growth.
Smart Images

Figure BDA0004232117950000011 
Figure BDA0004232117950000051 
Figure BDA0004232117950000061
Abstract
Description
Technical Field
[0001] The present disclosure relates to the field of gene therapy for breast cancer, and specifically to the use of a fully phosphorothioated antisense oligonucleotide targeting the insulin-like growth factor-1 receptor IGF1R gene or a composition thereof in inhibiting breast cancer cell proliferation and treating breast cancer. Background Art
[0002] Antisense oligonucleotide (ASODN) is a type of artificially synthesized oligonucleotide fragment with a length of 15 to 30 nucleotides. It mainly interferes with the transcription and translation of target genes through the principle of base complementary pairing, thereby achieving targeted gene therapy. ASODN has the advantages of abundant candidate targets, rational directional design, high efficiency in vitro and in vivo, and large-scale artificial synthesis. It is considered to be a highly promising gene therapy drug. In recent years, with the breakthroughs in nucleotide chemical modification technology and delivery technology, ASODN drug research and development has set off a new wave. Some well-known pharmaceutical companies at home and abroad have taken antisense drugs as one of the key directions of their new drug research and development. Currently, 9 antisense oligonucleotide drugs have been launched on the market (Table 1).
[0003] Table 1 Antisense oligonucleotide drugs on the market
[0004]
[0005] According to the latest data from the International Agency for Research on Cancer (IARC) survey in 2018, the incidence of breast cancer in women worldwide is 24.2%, ranking first among female cancers, of which 52.9% occur in developing countries. In my country, the incidence of breast cancer is increasing year by year, with more than 300,000 women diagnosed with breast cancer each year. The increase in the incidence of breast cancer is particularly obvious in the eastern coastal areas and economically developed cities. In terms of age of onset, the incidence of breast cancer in my country has gradually increased since the age of 20, reaching a high value at the age of 45 to 50. With the popularization of new treatment strategies and methods, the global mortality rate of breast cancer has gradually decreased. However, in China, especially in the vast rural areas, the downward trend in the mortality rate of breast cancer is not significant.
[0006] The breast is the target organ of many endocrine hormones, among which estrone and estradiol are directly related to the incidence of breast cancer. Early menarche (<12 years old), late menopause (>55 years old), infertility and late first childbirth (>30 years old), short breastfeeding time, estrogen replacement therapy after menopause, etc. can increase or prolong the exposure of estrogen in the body and are closely related to the incidence of breast cancer.
[0007] The cause of breast cancer is still unclear. The breast is the target organ of many endocrine hormones, such as estrogen, progesterone and prolactin, among which estrone and estradiol are directly related to the incidence of breast cancer. The disease is rare before the age of 20, but the incidence rises rapidly after the age of 20, and is higher at the age of 45-50. The incidence continues to rise after menopause, which may be related to the increase in estrone content in the elderly. Early menarche, late menopause, infertility and the age of first full-term birth are all related to the incidence of breast cancer. Those with a history of breast cancer in their first-degree relatives have a 2-3 times higher risk of developing the disease than the general population. The relationship between benign breast diseases and breast cancer is still controversial. Most people believe that those with high epithelial hyperplasia or atypical hyperplasia in the breast lobules may be related to the incidence of breast cancer. In addition, overnutrition, obesity, and fatty diets can enhance or prolong the stimulation of estrogen on breast epithelial cells, thereby increasing the chance of developing the disease. In addition, environmental factors and lifestyle also have a certain relationship with the incidence of breast cancer.
[0008] The average doubling time of breast cancer cells is 90 days. Before a tumor can be found clinically, the tumor hides for an average of 12 years (6 to 20 years). Once a tumor occurs, it can develop in the following ways: local expansion, lymphatic spread, and hematogenous spread. If breast cancer is not treated or the medication is ineffective, it will gradually invade the following areas: lymph nodes, bones, lungs, liver, brain, pleural cavity, pericardial effusion, hypercalcemia, and spinal cord compression.
[0009] Breast cancer can spread directly to the surrounding areas, through lymphatic channels and blood flow. Lymph nodes should be the first barrier to prevent cancer cells from escaping from the primary tumor. If cancer cells can pass through the lymph node barrier, they will usually invade the supraclavicular lymph nodes and then invade the veins and enter the blood. In addition to metastasizing to the axillary lymph nodes, the azygos vein system can be connected to the internal vertebral vein through the intervertebral veins and the posterior group of the extravertebral venous plexus. The blood flow of the vertebral vein system and the vena cava can flow to each other when the intra-abdominal pressure changes. Therefore, some patients have metastases to the skull, spine, pelvis, etc. before metastases to the vena cava system (such as the lungs).
[0010] Treatments for breast cancer include surgical resection, radiotherapy, chemotherapy, and hormone therapy. Treatment of breast cancer may involve only one of these methods or a combination of several methods. The treatment method depends on the individual case and varies from person to person. It is also affected by other factors, including whether the patient is postmenopausal, health status, type of tumor, size, microscopic appearance, and whether it has spread beyond the breast.
[0011] Therefore, there is a need in the art to develop new drugs for the treatment of breast cancer. Summary of the invention
[0012] In this regard, the present invention discloses treating breast cancer by designing an antisense oligonucleotide S-ASODN-1 with a unique sequence targeting the insulin-like growth factor-1 receptor IGF1R. The results show that the antisense oligonucleotide can treat breast cancer, thus solving the above technical problems.
[0013] The present disclosure first discovered that antisense oligonucleotide S-ASODN-1 with a specific sequence targeting insulin-like growth factor-1 receptor IGF1R can effectively inhibit breast cancer cell proliferation and breast cancer tumor growth, and is used to treat breast cancer. In fact, none of the existing drugs for treating breast cancer that have been approved or entered the clinical stage target the insulin-like growth factor-1 receptor IGF1R. In addition, the indications of the drugs currently under development that target the IGF1R receptor do not involve breast cancer (see Tables 2 and 3 below for specific descriptions). In addition, not any antisense oligonucleotide targeting any sequence of IGF1R can treat breast cancer. The results of the cell proliferation inhibition experiment disclosed in the present disclosure show that the inhibitory activity of this series of full-thio antisense oligonucleotides on breast cancer cells varies greatly. For example, S-ASODN-1 has a significant inhibitory effect on activity, which is comparable to the effect of the positive control cisplatin; while other antisense oligonucleotide sequences S-ASODN-2, S-ASODN-3, S-ASODN-4, and S-ASODN-5 cannot inhibit breast cancer cell proliferation and breast cancer tumor growth, and cannot be used to treat breast cancer (see Example 2).
[0014] Breast cancer (BC) is one of the most common malignant tumors in women. According to statistics, the incidence rate accounts for 7-10% of all malignant tumors in the body. Its incidence is often related to genetics, and it is more common in women aged 40-60 and before and after menopause. It usually occurs in the breast glandular epithelial tissue. It is mostly female, and male breast cancer accounts for 0.5% to 1% of all breast cancer patients.
[0015] Every year, there are 1.35 million new cases of breast cancer in the world, of which 420,000 die, with an annual increase of 2%. In developed countries such as Western Europe and North America, the incidence of breast cancer ranks first among female cancers. The United States is the country with the highest incidence of breast cancer in the world. Breast cancer has become the first female tumor and the second cause of cancer death. The risk of a woman suffering from breast cancer in her lifetime is one in seven, and one in seven women will suffer from breast cancer. And this risk of disease increases with age. China was originally a low-incidence country, but in the past 20 years, the annual increase rate has been 4.6%. The incidence rate in China's large and medium-sized cities (especially coastal cities) is higher than that in rural and inland areas. It has become the first female tumor in large cities such as Beijing and Shanghai, and is currently the fifth in rural areas. According to statistics, more than 40,000 women die from this disease in China every year, and breast cancer has become one of the serious diseases that seriously threaten women's lives. The cause of breast cancer is still unclear. So far, scientists have not found the exact cause of breast cancer, but have discovered many high-risk factors related to the onset of breast cancer. As the high-risk factors for breast cancer continue to accumulate, the risk of disease will increase.
[0016] Table 2 introduces the drugs that have been approved or entered the clinical stage for the treatment of breast cancer. It can be seen from Table 2 that none of the drugs currently under research for the treatment of breast cancer targets the insulin-like growth factor-1 receptor IGF1R.
[0017]
[0018]
[0019]
[0020]
[0021]
[0022]
[0023]
[0024]
[0025]
[0026]
[0027]
[0028]
[0029]
[0030]
[0031]
[0032]
[0033]
[0034]
[0035]
[0036]
[0037]
[0038]
[0039]
[0040]
[0041] Insulin-like growth factors (IGFs), also known as somatomedins, include IGF-I and IGF-II. These growth factors can only exert their biological effects when bound to their receptor IGF1R. The insulin-like growth factor-1 receptor IGF1R belongs to the receptor tyrosine kinase family and is located on the cell membrane. After binding to IGFs, it dimerizes, allowing the tyrosine domains to approach and trigger autophosphorylation, which then activates intracellular RAS-RAF-MAPK, PI3K-PKB / AKT and other cell proliferation-related signaling pathways. The activation of IGF1R is crucial to stimulating the growth and survival of tumor cells.
[0042] Table 3 shows the indications of the drugs currently under development that target the IGF1R receptor, none of which involve breast cancer.
[0043] Table 3 Information on drugs under development targeting IGF1R receptor
[0044]
[0045] In brief, the present invention designs anti-tumor antisense oligonucleotides based on the disclosed mRNA sequence BC113610.1 of insulin-like growth factor-1 receptor IGF1R as a target. By comparing the sequence with GeneBank online blast, the selected target sequence has good specificity and will not interfere with the expression of other normal human genes. Several designed antisense oligonucleotides are fully thiolated to prolong the action time in vivo and synthesized by a solid phase method.
[0046] The results of the cell proliferation inhibition experiment disclosed in the present invention show that not all antisense oligonucleotides targeting any sequence of IGF1R can treat breast cancer, and the inhibitory effects of this series of all-phosphorylation antisense oligonucleotides on breast cancer cells vary greatly. Among them, S-ASODN-1 has a significant inhibitory effect on activity, and is significantly better than the effect of the positive control cisplatin; on the contrary, other antisense oligonucleotide sequences S-ASODN-2, S-ASODN-3, S-ASODN-4, and S-ASODN-5 cannot inhibit breast cancer cell proliferation and breast cancer tumor growth, and cannot be used to treat breast cancer.
[0047] In addition, within the concentration range of 100-1600nM, S-ASODN-1 had different degrees of inhibitory effects on the proliferation of human breast cancer MCF7, BT474 and T47D cells. Among them, S-ASODN-1 had the best inhibitory effect on the human breast cancer cell line T47D. When the administration concentration of S-ASODN-1 was 1600nM, the inhibition rates of MCF7, BT474 and T47D cells at 24h were 52.32%, 61.05% and 63.88% respectively; the inhibition rates at 48h were 57.60%, 63.50% and 68.05% respectively; and the inhibition rates at 72h were 61.80%, 65.33% and 70.76% respectively.
[0048] Moreover, the inhibitory effect of S-ASODN-1 on the proliferation of various breast cancer cells is dose-dependent. As the concentration of S-ASODN-1 increases, the inhibitory effect on cell proliferation gradually increases. The inhibitory effect of S-ASODN-1 on the proliferation of various human breast cancer cell lines is sustained. The activity of S-ASODN-1 in inhibiting cell proliferation gradually increases within one to three days.
[0049] The results of the growth inhibition experiment on the human breast cancer cell line MCF7, BT474 and T47D transplanted tumor models showed that all the administration groups of S-ASODN-1 had an inhibitory effect on the tumor growth of human breast cancer cells. The inhibitory effect of the medium-dose group (7.5 mg / kg) was equivalent to that of the positive control sorafenib group (20 mg / kg), and the inhibitory effect of the high-dose group (15 mg / kg) was significantly better than that of the positive control sorafenib. Different dose groups can effectively inhibit the growth of breast cancer tumors.
[0050] Therefore, targeting the insulin-like growth factor-1 receptor ICF1R is used to treat breast cancer.
[0051] Specifically, the present disclosure provides the following technical solutions:
[0052] On the one hand, the present disclosure relates to the use of a therapeutically effective amount of a thiocyanate antisense oligonucleotide targeting an IGF1R gene or a composition thereof in the preparation of a medicament for inhibiting breast cancer cell proliferation and / or treating breast cancer in a subject suffering from breast cancer, wherein the sequence of the thiocyanate antisense oligonucleotide targeting an IGF1R gene comprises a nucleotide sequence having more than 80% nucleotide identity with the 5'-TCCTCCGGAGCCAGACTTCA-3' sequence, preferably a nucleotide sequence having more than 85%, 90%, 95%, 96%, 97%, 98%, or 99% nucleotide identity; more preferably, the sequence of the thiocyanate antisense oligonucleotide targeting an IGF1R gene is 5'-TCCTCCGGAGCCAGACTTCA-3' (SEQ ID NO: 1).
[0053] The term "nucleotide identity" refers to the percentage of the number of identical nucleotides in two nucleotide sequences to the number of nucleotides in one of the nucleotide sequences. For example, the sequence shown in SEQ ID NO:6 is 5'-TCCTCCGGAGCCAGACTTCA-3' (20 nucleotides), and the sequence shown in SEQ ID NO:7 is TCCTCCGGAGCCAGACTT (18 nucleotides). SEQ ID NO:7 and SEQ ID NO:6 have 90% nucleotide identity.
[0054] The term "therapeutically effective amount" or "therapeutically effective dose" refers to an amount of a substance, compound, material, or composition comprising a compound that is at least sufficient to produce a therapeutic effect after administration to a subject. Therefore, it is the amount necessary to prevent, cure, improve, block, or partially block the symptoms of a disease or disorder.
[0055] In a preferred embodiment, in the use of the therapeutically effective amount of the thiocyanate antisense oligonucleotide targeting IGF1R gene or the composition thereof disclosed in the present invention, the thiocyanate antisense oligonucleotide targeting IGF1R gene further has other chemical modifications.
[0056] In a preferred embodiment, in the use of a therapeutically effective amount of a phosphorothioate antisense oligonucleotide targeting IGF1R gene or a composition thereof disclosed herein, the other chemical modifications are selected from one or more of the following: locked nucleic acid modification, 2-methoxyethyl modification, 2-oxymethyl modification.
[0057] In a preferred embodiment, in the use of a therapeutically effective amount of a phosphorothioate antisense oligonucleotide targeting IGF1R gene or a composition thereof disclosed herein, the composition further comprises at least one additional active agent.
[0058] In a preferred embodiment, in the use of the therapeutically effective amount of phosphorothioate antisense oligonucleotides targeting IGF1R gene or a composition thereof disclosed herein, the at least one additional active agent is a therapeutic agent or a non-therapeutic agent, or a combination of a therapeutic agent and a non-therapeutic agent.
[0059] In a preferred embodiment, in the use of a therapeutically effective amount of a phosphorothioate antisense oligonucleotide targeting an IGF1R gene or a composition thereof disclosed herein, wherein the at least one additional active agent is a therapeutic agent selected from one or more of the following: encequidar, paclitaxel, dalpiciclib, oraxol, camrelizumab, AK112, QL1604, 609a, afuresertib, BEBT-209, SHR-A1811, CPO-100, 18F-estradiol, trastuzumab, mitomycin, leuprorelin, talzenna, tamoxifen, Inetetamab, ixabepilone, eutecticin, tamoxifen ... Delon, everolimus, exemestane, ribociclib, capecitabine, carmofur, doxifluridine, gemcitabine, pyrotinib, pirarubicin, palbociclib, denosumab, doxorubicin, docetaxel, neratinib, olaparib, tucatinib, urodipeptide, buserelin, pembrolizumab, pertuzumab, sacituzumabgovitecan), goserelin, toremifene, lapatinib, recombinant human hyaluronidase, letrozole, fluorouracil, fulvestrant, chloroquine, fadrozole, lobaplatin, cyclothiodine, cyclophosphamide, methotrexate, methyltestosterone, formestane, mitoxantrone, paclitaxel albumin, mesandrostane, eribulin, epirubicin, tucidinostat, bevacizumab, megestrol acetate, vindesine, vinblastine, alpelisib, atezolizumab, abemaciclib, anaphylaxis anastrozole, estradiol, raloxifene, margetuximab, infugem, myocet, SYP-0704A, LB-100, citoplurikin, maveropepimut-S, AIC100, DS-1205, amivantamab, capmatinib, belinostat, zimberelimab, onivyde, teterimumab, CDX-301, carotuximab, datopotamab deruxtecan), mupadolimab, tiragolumab, paxlovid, rose bengal, abexinostat, naptumomabestafenatox, telazorlimab, AC101, CDX-1140, CX-02, CYH33, DP303c, E7090, M9241, MRx0518, SGT-53, TQ-B3525, TT-00420, abeotaxane, autogene cevumeran, camidanlumabtesirine, ciforadenant, UC-961 (cirmtuzumab), endovion, AB928 (etrumadenant), indatuximabravtansine, minnelide, ACY-1215 (ricolinostat), AZD2014 (vistusertib), vudalimab, CGEN-15029, DF6002, INCAGN2385, MEN1611, NMS-P293, SGN-TGT, TPST-1120, UAB30, elimusertib, EOS100850 (inupadenant), DCC-2036 (rebastinib), 111In-pertuzumab, 188Re-NM-02, 18F-4-fluoroglutamine (18F labeled 4-fluoroglutamine), 64Cu-DOTAB-Fab, 64Cu-DOTA-trastuzumab, 68Ga-NOTA-BBN-RGD, 68Ga-NOTA-RM26, 820TCR, 89Zr-pertuzumab (pertuzumab), 99m-Tc-NM-02 , 99mTc-ABH2, 99mTc-HE3-G3, 99mTc-HPArk2, ABSK021, AC0682, ACE1702, ALT-P7, AMX3009, ASN004, ATRC-101, AU-002, AVA6000, AZD5305, AZD8701, B002, BAY 2701439, BBI-3000, BCA101, BCD-115, BEBT-260, BI-CON-02, BNT114, BPI-16350, CAR-T cells recognizing EpCAM, CART-TnMUC1, CDX-527, CF33-hNIS-anti-PDL1, CRX100, D-0502, DCVax-Direct, DKY709, DNX-2440, DZD1516, DZD3969, Deflexifol, E7046, EP-101, EP-3 02. ERSM-5404, FNX006, FT500, GALE-302, GB251, GMI-1359, GNC-035, GNX102, GQ1001, H2NVAC, HER2Bi-aATC, HRS8807, HS-10352, HS234, HSP-MUC 1. HTMC0435, IBI315, ICTCAR043, IMT-1012, INCB106385, INO-1400, IPH5301, JCAR024, JS003, JS101, JX-929, KY1701, LCB14-0110, LSZ102, LX-039, LZM005, MAG-TN3, AS15, MB-103, MBS301, MP0317, MPT0B640, (177-lutetium) lutetium oxide octreotide, copanlisib, dostarlimab, ASG-22CE (enfortumabvedotin), infigratinib, lurbinectedin, pexidartinib, delutec, lenvatinib, talzenna, everolimus, sintilimab, crizotinib, cabergoline, palbociclib, pexmetinib, neratinib, pasireotide, pamiparib, enzalutamide, entrectinib, lasofoxifene (lasofoxifene), tislelizumab, venetoclax, cobimetinib, eribulin, avelumab, CC-486, leronlimab, retifanlimab, toluenesulfonamide, pucotenlimab, poziotiso, cediranib, dalpiciclib, HE071, ALT-803, GR1405, MK-7684A, PANVAC-VF, SHR-1701, TVB-2640, Vigil, M7824 (bintrafusp alfa), bisindole, enobosarm, TAS-120 (futibatinib), GDC-0077 (inavolisib), magrolimab, monalizumab, nemvaleukinalfa, odetiglucan, AN1004 (pelareorep), SM-88 (racemetyrosine), spartalizumab, tusamitamabravtansine), utomilumab, vidutolimod, zanidatamab, β-D-mannuronic acid, entinostat, ropeporfin, sulforaphane, chiauranib, acolbifene, estratetrol, ThermoDox, 89Zr-girentuximab, L-monomethylarginine, indoximod, zilovertamab vedotin, upamostat, varlitinib, lucitanib, 18F-FFNP, 18F-dihydrotestosterone, 68Ga-NeoBOMB1, 68GaNOTA-anti-HER2 VHH1, A166, AE37, AVID100, AVX901, BAY85-8102, BMS-906024, BP-C1, CB-103, CFI-400945, DAC-001, DEP-irinotecan, ENMD-2076, EP-301, Elenagen, GP2 peptide, GSK3326595, HS-10342, INXN-2001, ImmunoPulse IL-12, LCL161, LUM015, MRG002, ONC201, P10s-PADRE vaccine, PF-06873600, PF-07104091, PVX-410, RAPA-201, RX-5902, SC10914, SCT200, SD-101, SG001, SHR2554, SHR7390, TPIV 110, TPIV 200, TQ-B3616, WOKVAC, ZEN-3694, anbenitamab, bemcentinib, AZD6738 (ceralasertib), eftilagimod alpha, eganelisib, grapiprant, ieramilimab, inCVAX, lacnotuzumab, ladiratuzumab vedotin, olinvacimab, pacmilimab, patritumab deruxtecan), AVB-620 (pegloprastide), peptide loaded dendritic cell immune peptidevaccine), CX-5461 (pidnarulex), plocabulin, praluzatamab ravtansine, LY3023414 (samotolisib), stenoparib, taminadenant, CB-839 (telaglenastat), eFT508 (tomivosertib), uliledlimab, uprosertib, varisacumab, INXN-1001 (veledimex), AZD2014 (vistusertib), xentuzumab, zelenoleucel, zenocutuzumab, efavirenz, endoxifen (en doxifen, capecitabine, cyclophosphamide, onapristone, tenalisib, taxane, serabelisib, epertinib, celetinib, cisplatin, vinblastine, 2X-111, KORTUC, LiPlaCis, ModraDoc006, Sarcodoxome, ixabepilone, zoledronic acid, anlotinib, niraparib, endostatin, enzalutamide, sacituzumab govitecan), Trilaciclib, Tegafur, uracil, tegafur, bicalutamide, fluzoparib, toripalimab, nivolumab, disitamab vedotin, alpelisib, apatinib, atezolizumab, avelumab, pegylated liposome doxorubicin, serplulimab, FCN-437c, GLSI-100, Hemay022, TAA013, TQB2450, OBI-822 (adagloxadsimolenin), SAR439859 (amcenestrant), POL6326 (balixafortide), buparlisib, AZD-9833 (camizestrant), AZD5363 (capivasertib), datopotamab deruxtecan, enobosarm, etirinotecan pegol), GDC-9545 (giredestrant), LY3484356 (imlunestrant), GDC-0077 (inavolisib), GDC-0068 (ipatasertib), G1T38 (lerociclib), NPS (nelipepimut-S), GDC-0032 (taselisib), birociclib, dimesna, entinostat, veliparib, elacestrant, EndoTAG-1, LY01005, NK105, olaparib, mitoxantrone, eryaspase, bavituximab, ARX788, tezatabep maltraxetan, testosterone, anastrozole, fruquintinib, durvalumab, binimetinib, pacritinib, pucotenlimab, dalpiciclib, KN046, bempegaldesleukin, galinpepimut-S, AMD-070 (mavorixafor), sapacitabine, BLEX404, CVA21, GEN1046, HS636, Nerofe, PDL1.t-haNK, PT-112, Teleukin, GSK2110183 (afuresertib), APG-2575 (lisaftoclax), PD0325901 (mirdametinib), oleclumab, VT-464 (seviteronel), EDO-S101 (tinostamustine), CDD-450 (zunsemetinib), bitinib, 111-In-ABY-025, 177Lu-NeoB, AK-01, AMXI-5001, ART4215, ARV-471, ATA2271, AZD8205, BEBT-209, BPI-1178, BPX-603, BT8009, BriaVax, CAM- H2, CFI-402257, ESG-401, FAZ053, GB1275, GEN1044, H3B-6545, HER2-CAR-T, IMGC936, NBE-002, NC76 2. NGM707, NKTR-262, NUV-422, OC-001, OMO-103, OP-1250, ORIN1001, REGN7075, RIVAL-01, S81694, SB T6050, SKB264, ST-067, TAEK-VAC, TAS0728, VX-803, ZN-c5, benufutamab, FP-1305 (bexmarilimab), eFT226, CAN04 (nadunolimab), triciribine phosphate, autologous tumor-infiltrating lymphocytes, recombinant human copper-zinc superoxide dismutase, and GLG-801.
[0060] In a preferred embodiment, in the use of the therapeutically effective amount of phosphorothioate antisense oligonucleotides targeting IGF1R gene or a composition thereof disclosed herein, the at least one additional active agent is a non-therapeutic agent.
[0061] In a preferred embodiment, in the use of a therapeutically effective amount of a phosphorothioate antisense oligonucleotide targeting IGF1R gene or a composition thereof disclosed herein, the non-therapeutic agent is selected from: antiemetics, anti-anemic drugs, anti-mucositis drugs, hypoglycemic drugs, hypolipidemic drugs, and antihypertensive drugs.
[0062] In a preferred embodiment, in the use of the therapeutically effective amount of the IGF1R gene-targeting antisense oligonucleotide or a composition thereof disclosed herein, the non-therapeutic agent is selected from: ondansetron, granisetron, dolasetron, palonosetron, metformin, simvastatin, lacidipine.
[0063] In a preferred embodiment, in the use of a therapeutically effective amount of a phosphorothioate antisense oligonucleotide targeting IGF1R gene or a composition thereof disclosed herein, wherein, according to pathological cytological classification, the breast cancer is selected from non-invasive cancer, invasive cancer, other rare cancers and combinations thereof.
[0064] In a preferred embodiment, in the use of a therapeutically effective amount of a phosphorothioate antisense oligonucleotide targeting IGF1R gene or a composition thereof disclosed herein, the non-invasive cancer is selected from intraductal carcinoma, lobular carcinoma in situ, intraductal papillary carcinoma, papillary eczematoid breast cancer and a combination thereof.
[0065] The invasive cancer is selected from invasive special cancer and / or invasive non-special cancer.
[0066] The invasive special carcinoma is selected from the group consisting of papillary carcinoma, medullary carcinoma, tubular carcinoma, adenoid cystic carcinoma, mucinous adenocarcinoma, apocrine carcinoma, squamous cell carcinoma, and combinations thereof.
[0067] The invasive carcinoma not otherwise specified is selected from the group consisting of invasive ductal carcinoma, invasive lobular carcinoma, scirrhous carcinoma, medullary carcinoma, simple carcinoma, adenocarcinoma, and combinations thereof.
[0068] In a preferred embodiment, in the use of the therapeutically effective amount of phosphorothioate antisense oligonucleotides targeting IGF1R gene or a composition thereof disclosed herein, the breast cancer is ductal carcinoma.
[0069] In a preferred embodiment, in the use of a therapeutically effective amount of a phosphorothioate antisense oligonucleotide targeting the IGF1R gene or a composition thereof disclosed herein, the cells involved in breast cancer are selected from one or more of the following according to pathological cytological classification: human breast cancer cell line MCF7, human breast cancer cell line T47D, and human breast cancer cell line BT474.
[0070] In a preferred embodiment, in the use of the therapeutically effective amount of the thiocyanate antisense oligonucleotide targeting IGF1R gene or the composition thereof disclosed herein, the thiocyanate antisense oligonucleotide targeting IGF1R gene or the composition thereof is formulated as a lyophilized agent or an injection.
[0071] In a preferred embodiment, in the use of a therapeutically effective amount of a thiocyanate antisense oligonucleotide targeting IGF1R gene or a composition thereof disclosed herein, the thiocyanate antisense oligonucleotide targeting IGF1R gene or a composition thereof is used in combination with one or more anti-cancer therapies, one or more cytostatic, cytotoxic or anticancer agents, targeted therapies, or a combination of any of the foregoing.
[0072] In a preferred embodiment, in the use of the therapeutically effective amount of phosphorothioate antisense oligonucleotides targeting IGF1R gene or a composition thereof disclosed herein, the anticancer therapy is selected from: chemotherapy, radiotherapy, biological therapy, bone marrow transplantation, stem cell transplantation.
[0073] The phosphorothioate antisense oligonucleotide targeting IGF1R gene or its composition or therapeutic combination disclosed herein is administered at an appropriate dose depending on different circumstances including the pharmacokinetics, pharmacodynamics, administration mode, administration route, age, mental state, gastrointestinal function state of the recipient, severity of the disease and duration of treatment, etc. of the specific drug.
[0074] The beneficial effects achieved by the present disclosure are at least as follows:
[0075] The present invention discloses a fully sulfhydryl antisense oligonucleotide S-ASODN-1 designed and synthesized with the mRNA sequence of insulin-like growth factor-1 receptor IGF1R as the target, which has a good effect in treating breast cancer.
[0076] 1. The fully sulfur-substituted antisense oligonucleotide S-ASODN-1 has a significant effect in inhibiting the proliferation of human breast cancer cells.
[0077] For example, S-ASODN-1 exhibited significant cell proliferation inhibitory effects on human breast cancer cell lines MCF7, BT474, and T47D.
[0078] 1-1. Within 24 to 72 hours of action, S-ASODN-1 has a significant inhibitory effect on a variety of human breast cancer cells, while S-ASODN-2 to 5 have no inhibitory effect.
[0079] The experimental results show that not all antisense oligonucleotides targeting IGF1R can treat breast cancer. The inhibitory activity of this series of all-phosphorylation antisense oligonucleotides on breast cancer cells varies greatly. Among them, S-ASODN-1 has a significant inhibitory effect on proliferation, and is significantly better than the positive control cisplatin; while other antisense oligonucleotide sequences S-ASODN-2, S-ASODN-3, S-ASODN-4, and S-ASODN-5 cannot effectively inhibit breast cancer cell proliferation and breast cancer tumor growth, and cannot be used to treat breast cancer.
[0080] 1-2. Within the treatment time of 24h to 72h, S-ASODN-1 has a significant inhibitory effect on the proliferation of various human breast cancer cells. Taking MCF7, BT474 and T47D cells as examples, the inhibitory effect on T47D is the best.
[0081] Specifically, when the dosage concentration of S-ASODN-1 was 1600nM, the inhibition rates of MCF7, BT474 and T47D cells after 24h of action time were 52.32%, 61.05% and 63.88% respectively; the inhibition rates after 48h of action time were 57.60%, 63.50% and 68.05% respectively; the inhibition rates after 72h of action time were 61.80%, 65.33% and 70.76% respectively.
[0082] 1-3. S-ASODN-1 has a dose-dependent inhibitory effect on the proliferation of breast cancer cells.
[0083] The proliferation inhibitory effect of S-ASODN-1 on various breast cancer cells (eg, MCF7, BT474 and T47D cell lines) is dose-dependent, and as the concentration of S-ASODN-1 increases, the inhibitory effect on cell proliferation gradually increases.
[0084] 1-4. S-ASODN-1 has a sustained inhibitory effect on the proliferation of human breast cancer cells.
[0085] The inhibitory effect of S-ASODN-1 on the proliferation of various human breast cancer cell lines (eg, MCF7, BT474 and T47D cell lines) was sustained. The inhibitory activity of S-ASODN-1 on cell proliferation gradually increased from one to three days.
[0086] 2. The fully sulfur-substituted antisense oligonucleotide S-ASODN-1 has a significant effect in inhibiting the growth of human breast cancer tumors in mice.
[0087] 2-1. S-ASODN-1 has a significant inhibitory effect on the growth of subcutaneous human breast cancer tumors in nude mice.
[0088] Among them, the results of the growth inhibition experiment of human breast cancer cell lines MCF7, BT474 and T47D subcutaneous tumor models showed that each S-ASODN-1 administration group had an inhibitory effect on the growth of human breast cancer cell tumors, the medium-dose group (7.5 mg / kg) was equivalent to the positive control sorafenib group (20 mg / kg), and the high-dose group (15 mg / kg) had an inhibitory effect significantly better than the positive control sorafenib. Different dose groups can effectively inhibit the growth of breast cancer tumors, and S-ASODN-1 can be used to treat breast cancer. BRIEF DESCRIPTION OF THE DRAWINGS
[0089] Figure 1This is a graph showing the inhibitory effect of S-ASODN-1 at different concentrations and treatment times on the proliferation of human breast cancer cell line MCF7;
[0090] Figure 2 This is a graph showing the inhibitory effect of S-ASODN-1 at different concentrations and treatment times on the proliferation of human breast cancer cell line BT474;
[0091] Figure 3 This is a graph showing the inhibitory effect of S-ASODN-1 at different concentrations and treatment times on the proliferation of human breast cancer cell line T47D;
[0092] Figure 4 The effect of S-ASODN-1 on the tumor weight of mice bearing the human breast cancer cell line MCF7;
[0093] Figure 5 The effect of S-ASODN-1 on the tumor weight of mice bearing the human breast cancer cell line BT474;
[0094] Figure 6 The effect of S-ASODN-1 on the tumor weight of mice bearing the human breast cancer cell line T47D. DETAILED DESCRIPTION
[0095] Example
[0096] Example 1: Synthesis of all-phosphorothioate antisense oligonucleotides
[0097] 1. Synthesis of all-phosphorothioate antisense oligonucleotide S-ASODN-1
[0098] S-ASODN-1 (sequence: 5'-TCCTCCGGAGCCAGACTTCA-3' (SEQ ID NO: 1)) was synthesized by solid phase synthesis using an OligoPilot 400 synthesizer from GE, USA. The synthesis steps are as follows:
[0099] 1) Deprotection
[0100] A toluene solution of dichloroacetic acid is used as a deprotection agent to remove the 5'-DMT protecting group of the starting nucleoside dA(bz) on the carrier, thereby releasing the 5'-hydroxyl group.
[0101] 2) Coupling
[0102] Acetonitrile is used as solvent and 5-ethylthiotetrazolyl is used as an activating agent to activate the dC(bz) phosphoramidite monomer to form an active intermediate, which then undergoes a condensation reaction with the 5'-hydroxyl group of the nucleoside dA(bz) for coupling.
[0103] 3) Thio
[0104] Using hydrogenated xanthan gum as the thiolation agent, phosphites are oxidized into stable thiophosphates.
[0105] 4) Hydroxyl protection
[0106] Acetic anhydride is used as a protecting agent to protect the 5'-hydroxyl group of the nucleoside that has not undergone coupling reaction.
[0107] Repeat the above steps 1)-4) until the S-ASODN sequence coupling is completed.
[0108] 5) Deprotection
[0109] Using dichloroacetic acid as a deprotection agent, the DMT protecting group of the last nucleoside dT is removed to obtain S-ASODN-1 connected to a carrier.
[0110] 6) Aminolysis
[0111] Add concentrated ammonia water to carry out aminolysis reaction, hydrolyze the ester bond between the carrier and the nucleotide, and remove the protecting groups on phosphate, adenine, guanine and cytosine. Filter, rinse with ethanol aqueous solution, and collect the filtrate.
[0112] 7) Purification
[0113] The filtrate was subjected to reverse phase column chromatography and freeze-dried to obtain the product with a purity of 94.80%.
[0114] 2. Synthesis of all-phosphorylation antisense oligonucleotides S-ASODN-2-5
[0115] The synthesis methods of the all-phosphorus antisense oligonucleotides S-ASODN-2 (sequence: 5'-TTCATTCCTTTTATTTGGGA-3' (SEQ ID NO: 2)), S-ASODN-3 (sequence: 5'-GGACCCTCCTCCGGAGCC-3' (SEQ ID NO: 3)), S-ASODN-4 (sequence: 5'-GAGAAACAGGAGCCCCCACA-3' (SEQ ID NO: 4)) and S-ASODN-5 (sequence: 5'-GCGCGGCTGGAAAGCGCGTT-3' (SEQ ID NO: 5)) were the same as above, and the purities were 93.57%, 93.61%, 94.66%, 92.39%, respectively.
[0116] Example 2: Cell proliferation inhibition experiment
[0117] 1. Experimental Materials
[0118] Test samples: the fully phosphorothioated antisense oligonucleotides S-ASODN-1, S-ASODN-2, S-ASODN-3, S-ASODN-4 and S-ASODN-5 synthesized in Example 1.
[0119] Cell types: human breast cancer cell line MCF7 (Guangzhou Saiku Biotechnology Co., Ltd.), human breast cancer cell line T47D (Guangzhou Saiku Biotechnology Co., Ltd.), human breast cancer cell line BT474 (Guangzhou Saiku Biotechnology Co., Ltd.).
[0120] Positive control drug: Cisplatin
[0121] Drug solvent: Sodium chloride injection
[0122] 2. Experimental Methods
[0123] The WST-1 Cell Proliferation and Cytotoxicity Assay Kit (purchased from Shanghai Bio-Tech Biotechnology Co., Ltd., product number C0036) (MTT-like method) was used to detect the growth inhibition of the test samples on human glioma cell lines U87, U251, and SHG-44, with cisplatin as the positive control.
[0124] WST-1 cell proliferation and cytotoxicity detection kit includes WST-1 (powder)*1 bottle, electron coupling reagent*5mL.
[0125] Preparation of WST-1 solution: Add 5 ml of electron coupling reagent to WST-1 powder and dissolve it completely to form WST-1 solution.
[0126] In the experiment, 100 μL of 2,000 cells were added to each well for culture, and different concentrations and different all-phosphorylation antisense oligonucleotides were given for stimulation. 10 μL of WST-1 solution was added to each well, and the wells with the same amount of cell culture medium and WST-1 solution but no cells were used as blank controls. Incubate in the cell culture incubator for 1-2 hours, place the 96-well plate on a shaker and shake for 1 minute to fully mix the system to be tested, and measure the absorbance at 450 nm.
[0127] 2.1 Cell culture
[0128] Take the subcultured MCF7, BT474 and T47D cell lines, culture the logarithmically growing cells with 10% fetal bovine serum RPMI1640 culture medium (supplemented with 100 μL / mL of penicillin and streptomycin), place them in a cell culture incubator at 37°C containing 5% CO2, and change the medium once a day. Digest and subculture with 0.25% trypsin, centrifuge at 1000 r / min for 5 minutes, discard the supernatant, and add fresh culture medium for subculture.
[0129] 2.2 Cell transfection
[0130] Inoculate the cells into a 96-well plate in advance, with 5,000 cells per well, and replace with new culture medium before the experiment while ensuring that the cells adhere to the wall. Add 0.3 μL of Lipo3000 transfection reagent to 5 μL of Opti-MEM medium, shake to mix, and centrifuge instantly. Add the corresponding concentrations of the samples to be transfected (final concentrations are: 0nM, 100nM, 200nM, 400nM, 800nM, 1600nM) and 0.4 μL of P3000 reagent to 5 μL of Opti-MEM medium, shake to mix, and centrifuge instantly. Add the diluted samples to be transfected to each tube of diluted Lipo3000 reagent. Each mixing tube contains reagent components. Incubate at room temperature for 15 minutes, and add the incubated transfection reagent to the prepared cells.
[0131] In addition, a blank control group (no reagent was added, only cells) and a positive control group (cisplatin administration concentration was 5 μM) were set up.
[0132] 2.3 Cell proliferation assay
[0133] Use WST-1 cell proliferation and cytotoxicity kit for detection. Add 10 μL of WST-1 solution to 100 μL of culture medium. After incubation in the cell culture incubator for 1 hour, place the cell culture plate on a shaker for one minute to mix thoroughly, and measure the absorbance (OD) at 450 nm.
[0134] 2.4 Data Processing
[0135] The cell survival rate (%) and proliferation inhibition rate (%) were calculated using the following formula:
[0136] Survival rate (%) = (OD value of experimental group / OD value of blank control group) × 100%;
[0137] Inhibition rate (%) = 1 - survival rate (%).
[0138] 3. Experimental results
[0139] 3.1 When the action time was 72h, S-ASODN-1 had a significant inhibitory effect on a variety of human breast cancer cells, while S-ASODN-2~5 had no inhibitory effect
[0140] The experimental results showed that when the action time was 72h, S-ASODN-1 had the best inhibitory effect on the proliferation of human breast cancer MCF7, BT474 and T47D cells, showing inhibitory activity at 100nM. S-ASODN-2~5 had no inhibitory effect on the growth of human breast cancer cells in the concentration range of 0~1600nM.
[0141] The specific experimental results are as follows:
[0142] Table 4 Inhibitory effect of antisense oligonucleotide S-ASODN series on proliferation of human breast cancer cells
[0143]
[0144] As can be seen from Table 4, the synthesized all-sulfoantisense oligonucleotide sequences S-ASODN-2 to 5 had no inhibitory effect on the growth of human breast cancer MCF7, BT474 and T47D cells in the concentration range of 0 to 1600 nM. S-ASODN-1 had the best cell proliferation inhibitory effect, showing inhibitory activity at 100 nM, and the inhibitory effect increased with the increase of concentration. In addition, when the action time was 72 h, the inhibition rates of S-ASODN-1 at different administration concentrations on MCF7, BT474 and T47D cells were:
[0145] When the drug concentration was 100 nM, the inhibition rate after 72 hours of action was controlled at about 47% to 50%, showing a good inhibitory effect.
[0146] When the drug concentration was 200-800 nM, the inhibition rate with an action time of 72 h was controlled at about 50%-58%, and the inhibition effect showed a significant improvement compared with the drug concentration of 100 nM.
[0147] When the drug concentration was 1600nM, the inhibition rates after 72h of action were 61.80%, 65.33% and 70.76% respectively, all of which were greater than 60%. Moreover, when the drug concentration was 1600nM and the action time was 72h, the highest inhibition rate for T47D cells was 70.76%, with significant inhibition effect.
[0148] It can be seen that the inhibitory effects of antisense oligonucleotide sequences targeting the mRNA sequence of insulin-like growth factor-1 receptor IGF1R on breast cancer cells of different cell lines are very different. Not all antisense oligonucleotides targeting any sequence of IGF1R can treat breast cancer. For example, antisense oligonucleotide S-ASODN-1 with a specific sequence targeting insulin-like growth factor-1 receptor IGF1R can effectively inhibit the proliferation of multiple breast cancer cells and is used to treat breast cancer. On the contrary, other antisense oligonucleotide sequences S-ASODN-2, S-ASODN-3, S-ASODN-4 and S-ASODN-5 disclosed in the present invention cannot inhibit the proliferation of breast cancer cells and cannot be used to treat breast cancer.
[0149] 3.2 Within the treatment time of 24h to 72h, S-ASODN-1 had a significant inhibitory effect on the proliferation of various human breast cancer cells, among which the inhibitory effect on T47D was the best.
[0150] The above experiment investigated the inhibitory effect of the antisense oligonucleotide sequence S-ASODN-1~5 series on the proliferation of human breast cancer MCF7, BT474 and T47D cells. It was found that only S-ASODN-1 had a significant inhibitory effect on the above human breast cancer cell lines, while the other S-ASODN-2~5 had no inhibitory effect.
[0151] The following content further explores the inhibitory effect of S-ASODN-1 on human breast cancer cell proliferation at different action times.
[0152] The results showed that S-ASODN-1 had an inhibitory effect on the proliferation of human breast cancer cell lines MCF7, BT474 and T47D within 24h to 72h, and had the best inhibitory effect on T47D.
[0153] The specific experimental results are as follows:
[0154] Table 5 Inhibitory effect of antisense oligonucleotide S-ASODN-1 on proliferation of human breast cancer cells
[0155]
[0156]
[0157] From Table 5 and Figure 1-3 It can be seen that S-ASODN-1 has an inhibitory effect on the proliferation of human breast cancer cell lines MCF7, BT474 and T47D.
[0158] 1) Inhibitory effect on MCF7 cell line
[0159] S-ASODN-1 can inhibit the proliferation of MCF7 cell line at a concentration of 100 nM, with the inhibition rate of 43.89% at 24 h, 45.15% at 48 h, and 47.95% at 72 h;
[0160] At 200nM concentration, the inhibition rate of MCF7 cell line was 45.75% for 24h, 48.24% for 48h, and 50.25% for 72h; at 400nM concentration, the inhibition rate of MCF7 cell line was 47.94% for 24h, 50.19% for 48h, and 52.92% for 72h; at 800nM concentration, the inhibition rate of MCF7 cell line was 51.10% for 24h, 53.27% for 48h, and 55.56% for 72h; at 1600nM concentration, the inhibition rate of MCF7 cell line was 52.32% for 24h, 57.60% for 48h, and 61.80% for 72h. The inhibitory effects of 100-1600nM were higher than the positive control, and the inhibition rates of 800nM and 1600nM were more than 50% in 24-72h.
[0161] 2) Inhibitory effect on BT474 cell line
[0162] S-ASODN-1 can inhibit the proliferation of BT474 cell line at a concentration of 100nM, which is higher than the positive control. With the extension of the action time, the inhibition rate shows a steady increase trend at the concentration of 100nM to 1600nM. Under 24h conditions, the inhibition rates of 100nM, 200nM, 400nM, 800nM and 1600nM were 47.44%, 49.32%, 50.04%, 52.31% and 61.05%, respectively. Under 48h conditions, the inhibition rates of 100nM, 200nM, 400nM, 800nM and 1600nM were 48.47%, 49.47%, 51.69%, 53.38% and 63.50%, respectively. Under the condition of 72h, the inhibition rates at different administration concentrations of 100nM, 200nM, 400nM, 800nM and 1600nM were 49.28%, 51.50%, 53.18%, 55.58% and 65.33% respectively. The inhibitory effects of 100-1600nM were significantly higher than those of the positive control.
[0163] 3) Inhibitory effect on T47D cell line
[0164] S-ASODN-1 can inhibit the proliferation of T47D cell line at a concentration of 100nM within 24h, and the effect is higher than that of the positive control. With the extension of the action time, the inhibition rate shows a steady increase trend at a concentration of 100nM to 1600nM. Under 24h conditions, the inhibition rate reached 47.11% to 63.88% at different administration concentrations of 100 to 1600nM, which is significantly higher than the inhibitory effect of the positive control at 24h (39.78%).
[0165] Under 48h conditions, at different drug concentrations of 100-1600nM, the inhibition rates were in the range of 48.75%-68.05%, which were significantly higher than the inhibition effect of the positive control at 48h (41.53%).
[0166] Under 72h conditions, at different dosage concentrations of 100-1600nM, the inhibition rates were as high as 49.60%-70.76%, which were higher than the inhibition effect of the positive control at 72h (44.26%), and the highest could exceed 26.5% of the inhibition rate of the positive control, with significant inhibition effect.
[0167] The experimental results showed that the inhibitory activity of this series of fully phosphorylated antisense oligonucleotides on lung cancer cells varied greatly. The antisense oligonucleotide sequence S-ASODN-1, which targets the mRNA sequence of insulin-like growth factor-1 receptor IGF1R, had a significant inhibitory effect on the proliferation of human breast cancer cell lines MCF7, BT474 and T47D.
[0168] As shown in Table 1, through statistical analysis, S-ASODN-1 showed significant growth inhibition on three cell lines, MCF7, BT474 and T47D, on the first day. Among them, S-ASODN-1 had the highest inhibitory effect on the human breast cancer cell line T47D. When the dosage concentration of S-ASODN-1 was 1600nM, the inhibition rates of MCF7, BT474 and T47D cells at 24h were 52.32%, 61.05% and 63.88% respectively; the inhibition rates at 48h were 57.60%, 63.50% and 68.05% respectively; and the inhibition rates at 72h were 61.80%, 65.33% and 70.76% respectively.
[0169] Compared with the control cisplatin inhibition rate, the order of improvement in the proliferation inhibition effect of S-ASODN-1 on each cell line (from large to small compared with the control cisplatin inhibition rate) is: T47D>BT474>MCF7, and the inhibition rate effect is significant.
[0170] 3.3S-ASODN-1 has a significant inhibitory effect on the proliferation of multiple human breast cancer cell lines
[0171] Based on the results of the above Table 5 on the inhibitory effect of S-ASODN-1 on human breast cancer cell proliferation at different time and concentration, the significance analysis of the survival rate of the cell proliferation inhibition test was performed.
[0172] The survival rates of different concentrations (100nM, 200nM, 400nM, 800nM, 1600nM) were compared with the negative group (0nM) and the blank control group (Mock group containing only the same cells without adding reagents) for significance analysis.
[0173] The proliferation inhibition test of each tumor cell line was repeated 3 times, and the survival rate was calculated. See the table below.
[0174] The t-test program in EXCEL software was used for statistical analysis between groups. The significance of the difference between the samples to be transfected at different concentrations and the blank group and the samples to be transfected at different concentrations and the negative group was analyzed. Among them, p<0.05, *, indicates a slight difference; p<0.01, **, indicates a significant difference; p<0.001, ***, indicates a highly significant difference.
[0175]
[0176]
[0177] As can be seen from the above table, for human breast cancer cells of different cell lines, as the dosage concentration increases from 100nM to 1600nM, and the action time prolongs from 24h to 72h, the p value obtained by the test is much less than 0.05, indicating that the survival rate of the experimental group is different from that of the blank group or the negative group; and, the p of the overall data in the above table is <0.001, indicating that the survival rate of the experimental group is highly significantly different from that of the blank group or the negative group, that is, S-ASODN-1 has a significant improvement and enhancement on the survival rate of human breast cancer MCF7, BT474 and T47D cell lines.
[0178] 3.4S-ASODN-1 inhibits the proliferation of breast cancer cell lines in a dose-dependent manner
[0179] From the above experimental results, it can be seen that S-ASODN-1 has a significant inhibitory effect on the proliferation of various breast cancer cell lines.
[0180] We further explored the relationship between the proliferation inhibitory effect of S-ASODN-1 on various breast cancer cell lines and the dose of S-ASODN-1, proving that its inhibitory effect is dose-dependent.
[0181] The results on the first day after cell transfection showed that as the concentration of S-ASODN-1 increased (100nM to 1600nM), the proliferation inhibition effect on human breast cancer cell lines was significantly enhanced.
[0182] Specifically: when the action time is 72h, the drug concentration is gradually increased, that is, the drug concentration is 100nM, 200nM, 400nM, 800nM and 1600nM respectively.
[0183] The inhibition rates of S-ASODN-1 on MCF7 cells were 47.95%, 50.25%, 52.92%, 55.56% and 61.80% respectively;
[0184] The inhibition rates of S-ASODN-1 on BT474 cells were 49.28%, 51.50%, 53.18%, 55.58% and 65.33% respectively;
[0185] The inhibition rates of S-ASODN-1 on T47D cells were 49.60%, 51.55%, 54.61%, 57.73% and 70.76% respectively.
[0186] From the above data, it can be seen that the proliferation inhibition rate of S-ASODN-1 on different human breast cancer cell lines increases with the increase of administration concentration, indicating that the proliferation inhibition of S-ASODN-1 on human breast cancer cell lines is dose-dependent.
[0187] 3.5S-ASODN-1 has a persistent inhibitory effect on the proliferation of human breast cancer cell lines
[0188] In addition to the above-mentioned study on the dose-dependence of the effect of S-ASODN-1, the duration of the proliferation inhibitory effect of S-ASODN-1 was also investigated in various human breast cancer cell lines. The results showed that the proliferation inhibitory effect of S-ASODN-1 on various human breast cancer cell lines was sustained.
[0189] The duration of action is not only an important indicator for evaluating antisense nucleic acid drugs, but also has important reference value for the dosing regimen. From the above experimental results, it can be seen that in breast cancer cells, the activity of S-ASODN-1 in inhibiting cell proliferation gradually increases from one to three days. On the third day, the inhibition rate of S-ASODN-1 on breast cancer cell proliferation can reach more than 50% to 70%, showing a significant inhibitory effect on breast cancer cell proliferation.
[0190] Specifically: when the administration concentration of S-ASODN-1 was 1600nM, as the administration time increased, the inhibition rates of MCF7 cells were 52.32%, 57.60% and 61.80% at administration times of 24h, 48h and 72h, respectively; the inhibition rates of BT474 cells were 61.05%, 63.50% and 65.33%, respectively; the inhibition rates of T47D cells were 63.88%, 68.05% and 70.76%, respectively. As the administration time increased, it exerted a significant inhibitory effect on human breast cancer MCF7, BT474 and T47D cells.
[0191] Based on the experimental results in the above examples, it was found that S-ASODN-1 exerted a significant proliferation inhibitory effect on human breast cancer MCF7, BT474 and T47D cells, and the effect was dose-dependent and persistent. Among them, S-ASODN-1 had the highest inhibitory effect on the human breast cancer cell line T47D. In addition, an experimental study was conducted on the growth inhibition of S-ASODN-1 on a nude mouse tumor model bearing subcutaneous human breast cancer.
[0192] Example 3: Experimental study on the growth inhibition of S-ASODN-1 in nude mice bearing subcutaneous human breast cancer tumors
[0193] 1. Experimental Materials
[0194] Test sample: the fully phosphorothioate antisense oligonucleotide S-ASODN-1 synthesized in Example 1
[0195] (Sequence: 5'-TCCTCCGGAGCCAGACTTCA-3')
[0196] Cell types: Human breast cancer cell lines MCF7, BT474 and T47D
[0197] Positive drug: Sorafenib
[0198] Drug solvent: Sodium chloride injection
[0199] Experimental animals: 4-6 weeks old Nu / Nu nude mice, weighing 20.0±2g, 100 males and females, purchased from Beijing Weitonglihua Experimental Animal Technology Co., Ltd. The test animals were housed in sterile independent ventilated IVC cages, with 5-6 mice per cage. The bedding was 60 Co radiation sterilized corn cob litter, particle size 4-6 mm. Feed with sterilized feed specially formulated for mice, free access to purified water. The temperature in the animal laboratory was maintained at around 25°C, the relative humidity was maintained at 40-70%, and the light was on for 12 hours per day.
[0200] 2. Experimental Methods
[0201] 2.1 Cell culture
[0202] MCF7, BT474 and T47D cells were cultured in RPMI 1640 cell culture medium containing 10% fetal bovine serum (supplemented with 100 μL / mL each of penicillin and streptomycin) in a cell culture incubator at 37°C and 5% CO2, and the medium was changed once a day. The cells were digested and subcultured with 0.25% trypsin, centrifuged at 1000 r / min for 5 minutes, the supernatant was discarded, and fresh culture medium was added for subculture.
[0203] 2.2 Preservation of subcutaneous transplanted tumor model
[0204] The subcultured human breast cancer cells MCF7, BT474 and T47D were digested into a suspension under sterile conditions, rinsed with sodium chloride injection and resuspended into a suspension, which was then subcutaneously inoculated into the axilla of the right forelimb of nude mice for seed preservation.
[0205] 2.3 Experimental groups and treatment plans:
[0206] One week after tumor cell inoculation, when tumor tissue bulges were observable with the naked eye, animals with similar tumor sizes were randomly grouped according to their weight. The mice were randomly divided into five groups, namely, the blank model control group (blank control group), S-ASODN-1 low-dose (3.75 mg / kg) group, S-ASODN-1 medium-dose (7.5 mg / kg) group, S-ASODN-1 high-dose (15 mg / kg) group and the positive control sorafenib (20 mg / kg) group.
[0207] Specific dosing and treatment methods for each group:
[0208] Blank model control group: A mouse breast cancer model was constructed according to the above method. After the model was successfully established, pure water was administered by gavage once every 24 hours for a total of 20 days. The body weight of the mice was measured at the beginning and after the completion of the experiment.
[0209] S-ASODN-1 low, medium and high dose groups: The mouse breast cancer model was constructed according to the above method. After the model was successfully established, each group of mice was injected with the given dose through the tail vein, which were low dose group: 3.75 mg / kg, medium dose group: 7.5 mg / kg and high dose group: 15 mg / kg. The dose was given once every 48 hours for 10 times in a row for a total of 20 days. The body weight of the mice was measured at the beginning and after the completion of the experiment.
[0210] Positive control group: A mouse breast cancer model was constructed according to the above method. After the model was successfully established, sorafenib was administered by oral gavage once every 24 hours for a total of 20 days. The body weights of the mice were measured at the beginning and after the completion of the experiment.
[0211] After the experiment, the animals were killed by cervical dislocation. The tumor tissue was removed by dissection, and the tumor visible to the naked eye was peeled off and weighed.
[0212] 2.4 Data Processing
[0213] Orthotopic transplant tumor weight data are expressed as X±S (mean±standard deviation);
[0214] Tumor net weight inhibition rate = (blank model control group tumor net weight - drug administration group tumor net weight) / blank model control group tumor net weight × 100%.
[0215] 3. Experimental results
[0216] Tumor weight directly reflects the size of breast cancer tumors. The curve trends of different groups show that the medium-dose group (7.5 mg / kg) of S-ASODN-1 has the same effect as the positive drug sorafenib group in inhibiting breast cancer, and the breast cancer inhibition rate of the S-ASODN-1 test drug is dose-dependent.
[0217]
[0218] As shown in the table above and Figure 4-6 As shown, during the drug administration period, animals in each group died except the blank model control group.
[0219] When the animals in the low-dose group were administered, there were no deaths in the MCF7 cell line, no deaths in the BT474 cell line, and no deaths in the T47D cell line.
[0220] In the medium-dose group, one animal of the MCF7 cell line died, three animals of the BT474 cell line died, and one animal of the T47D cell line died.
[0221] In the high-dose group, 2 animals of MCF7 cell line died, 1 animal of BT474 cell line died, and 2 animals of T47D cell line died.
[0222] When the animals in the positive control group were given the drug, 2 animals in the MCF7 cell line died, 2 animals in the BT474 cell line died, and 0 animals in the T47D cell line died.
[0223] For the MCF7 cell line, the tumor weights of each group were: 100.53±56.98mg for the blank model control group, 76.27±32.42mg for the positive control sorafenib group, 91.59±29.60mg for the low-dose S-ASODN-1 group, 85.66±39.64mg for the medium-dose group, and 46.50±15.51mg for the high-dose group. Compared with the blank model control group, each drug-treated group could significantly inhibit tumor growth. Among them, the high-dose group had the best tumor inhibition effect, which was significantly better than the positive control sorafenib.
[0224] For the BT474 cell line, the tumor weights of each group were: 107.11±65.85mg for the blank model control group, 71.94±42.76mg for the positive control sorafenib group, 83.13±40.42mg for the S-ASODN-1 low-dose group, 77.32±10.90mg for the medium-dose group, and 43.85±18.16mg for the high-dose group. Compared with the blank model control group, each drug-treated group could significantly inhibit tumor growth. Among them, the tumor inhibition effect of the medium-dose group was equivalent to that of the positive control sorafenib. The high-dose group had the best tumor inhibition effect, which was significantly better than the positive control sorafenib.
[0225] For the T47D cell line, the tumor weights of each group were: 97.66±53.25 mg for the blank model control group, 70.72±32.31 mg for the positive control sorafenib group, 76.42±48.34 mg for the S-ASODN-1 low-dose group, 57.68±23.69 mg for the medium-dose group, and 39.71±13.03 mg for the high-dose group. Compared with the blank model control group, each drug-treated group could significantly inhibit tumor growth. Among them, the low-dose group had an inhibitory effect comparable to that of the positive control sorafenib. The high-dose group had the best inhibitory effect, followed by the medium-dose group, and both had better inhibitory effects than the positive control sorafenib.
[0226] Compared with the blank model control group, the net tumor weight inhibition rates of the positive control sorafenib group in different experimental groups were MCF7: 24.13%, BT474: 32.83%, T47D: 27.74%; the net tumor weight inhibition rates of the low-dose group were MCF7: 8.89%, BT474: 22.40%, T47D: 21.90%; the net tumor weight inhibition rates of the medium-dose group were MCF7: 14.79%, BT474: 27.81%, T47D: 41.06%; the net tumor weight inhibition rates of the high-dose group were MCF7: 53.74%, BT474: 59.06%, T47D: 59.42%.
[0227] From the above data, it can be seen that each S-ASODN-1 administration group has a significant inhibitory effect on the growth of human breast cancer cell tumors. The low-dose group and the medium-dose group can achieve the same effect as the positive control sorafenib group. The inhibitory effect of the high-dose group is significantly better than the positive control sorafenib. Different dose groups can significantly inhibit the growth of breast cancer tumors and are used to treat breast cancer.
Claims
1. Use of a therapeutically effective amount of a thiocyanate antisense oligonucleotide targeting IGF1R gene or a composition thereof in the preparation of a medicament for inhibiting breast cancer cell proliferation and / or treating breast cancer in a subject suffering from breast cancer, wherein the sequence of the thiocyanate antisense oligonucleotide targeting IGF1R gene comprises a nucleotide sequence having more than 80% nucleotide identity with the sequence shown in SEQ ID NO:1, preferably a nucleotide sequence having more than 85%, 90%, 95%, 96%, 97%, 98%, 99% nucleotide identity; more preferably, the sequence of the thiocyanate antisense oligonucleotide targeting ICFIR gene is as shown in SEQ ID NO:
1.
2. The use according to claim 1, wherein the phosphorothioate antisense oligonucleotide targeting the IGF1R gene further has other chemical modifications.
3. The use according to claim 2, wherein the other chemical modifications are selected from one or more of the following: locked nucleic acid modification, 2-methoxyethyl modification and 2-oxymethyl modification.
4. Use according to any one of the preceding claims, wherein the composition further comprises at least one additional active agent.
5. The use according to claim 4, wherein the at least one additional active agent is a therapeutic agent or a non-therapeutic agent, or a combination of a therapeutic agent and a non-therapeutic agent.
6. The use according to claim 5, wherein the at least one additional active agent is a therapeutic agent selected from one or more of the following: encequidar, paclitaxel, dalpiciclib, oraxol, camrelizumab, AK112, QL1604, 609a, afuresertib, BEBT-209, SHR-A1811, CPO-100, 18F-estradiol, trastuzumab, mitomycin, leuprorelin, talzenna, tamoxifen, inetetamab, ixabepilone, eutilide, everolimus ), exemestane, ribociclib, capecitabine, carmofur, doxifluridine, gemcitabine, pyrotinib, pirarubicin, palbociclib, denosumab, doxorubicin, docetaxel, neratinib, olaparib, tucatinib, urodipeptide, buserelin, pembrolizumab, pertuzumab, sacituzumabgovitecan), goserelin, toremifene, lapatinib, recombinant human hyaluronidase, letrozole, fluorouracil, fulvestrant, chloroquine, fadrozole, lobaplatin, cyclothiodine, cyclophosphamide, methotrexate, methyltestosterone, formestane, mitoxantrone, paclitaxel albumin, mesandrostane, eribulin, epirubicin, tucidinostat, bevacizumab, megestrol acetate, vindesine, vinblastine, alpelisib, atezolizumab, abemaciclib, anaphylaxis anastrozole, estradiol, raloxifene, margetuximab, infugem, myocet, SYP-0704A, LB-100, citoplurikin, maveropepimut-S, AIC100, DS-1205, amivantamab, capmatinib, belinostat, zimberelimab, onivyde, teterimumab, CDX-301, carotuximab, datopotamab deruxtecan), mupadolimab, tiragolumab, paxlovid, rose bengal, abexinostat, naptumomabestafenatox, telazorlimab, AC101, CDX-1140, CX-02, CYH33, DP303c, E7090, M9241, MRx0518, SGT-53, TQ-B3525, TT-00420, abeotaxane, autogene cevumeran, camidanlumabtesirine, ciforadenant, UC-961 (cirmtuzumab), endovion, AB928 (etrumadenant), indatuximabravtansine, minnelide, ACY-1215 (ricolinostat), AZD2014 (vistusertib), vudalimab, CGEN-15029, DF6002, INCAGN2385, MEN1611, NMS-P293, SGN-TGT, TPST-1120, UAB30, elimusertib, EOS100850 (inupadenant), DCC-2036 (rebastinib), 111In-pertuzumab, 188Re-NM-02, 18F-4-fluoroglutamine (18F labeled 4-fluoroglutamine), 64Cu-DOTAB-Fab, 64Cu-DOTA-trastuzumab, 68Ga-NOTA-BBN-RGD, 68Ga-NOTA-RM26, 820TCR, 89Zr-pertuzumab, 99m-Tc-NM-02 , 99mTc-ABH2, 99mTc-HE3-G3, 99mTc-HPArk2, ABSK021, AC0682, ACE1702, ALT-P7, AMX3009, ASN004, ATRC-101, AU-002, AVA6000, AZD5305, AZD8701, B002, BAY 2701439, BBI-3000, BCA101, BCD-115, BEBT-260, BI-CON-02, BNT114, BPI-16350, CAR-T cells recognizing EpCAM, CART-TnMUC1, CDX-527, CF33-hNIS-anti-PDL1, CRX100, D-0502, DCVax-Direct, DKY709, DNX-2440, DZD1516, DZD3969, Deflexifol, E7046, EP-101, EP-3 02. ERSM-5404, FNX006, FT500, GALE-302, GB251, GMI-1359, GNC-035, GNX102, GQ1001, H2NVAC, HER2Bi-aATC, HRS8807, HS-10352, HS234, HSP-MUC 1. HTMC0435, IBI315, ICTCAR043, IMT-1012, INCB106385, INO-1400, IPH5301, JCAR024, JS003, JS101, JX-929, KY1701, LCB14-0110, LSZ102, LX-039, LZM005, MAG-TN3, AS15, MB-103, MBS301, MP0317, MPT0B640, (177-lutetium) lutetium oxide octreotide, copanlisib, dostarlimab, ASG-22CE (enfortumabvedotin), infigratinib, lurbinectedin, pexidartinib, delutec, lenvatinib, talzenna, everolimus, sintilimab, crizotinib, cabergoline, palbociclib, pexmetinib, neratinib, pasireotide, pamiparib, enzalutamide, entrectinib, lasofoxifene (lasofoxifene), tislelizumab, venetoclax, cobimetinib, eribulin, avelumab, CC-486, leronlimab, retifanlimab, toluenesulfonamide, pucotenlimab, poziotiso, cediranib, dalpiciclib, HE071, ALT-803, GR1405, MK-7684A, PANVAC-VF, SHR-1701, TVB-2640, Vigil, M7824 (bintrafusp alfa), bisindole, enobosarm, TAS-120 (futibatinib), GDC-0077 (inavolisib), magrolimab, monalizumab, nemvaleukinalfa, odetiglucan, AN1004 (pelareorep), SM-88 (racemetyrosine), spartalizumab, tusamitamabravtansine), utomilumab, vidutolimod, zanidatamab, β-D-mannuronic acid, entinostat, ropeporfin, sulforaphane, chiauranib, acolbifene, estratetrol, ThermoDox, 89Zr-girentuximab, L-monomethylarginine, indoximod, zilovertamab vedotin, upamostat, varlitinib, lucitanib, 18F-FFNP, 18F-dihydrotestosterone, 68Ga-NeoBOMB1, 68GaNOTA-anti-HER2 VHH1, A166, AE37, AVID100, AVX901, BAY85-8102, BMS-906024, BP-C1, CB-103, CFI-400945, DAC-001, DEP-irinotecan, ENMD-2076, EP-301, Elenagen, GP2 peptide, GSK3326595, HS-10342, INXN-2001, ImmunoPulse IL-12, LCL161, LUM015, MRG002, ONC201, P10s-PADRE vaccine, PF-06873600, PF-07104091, PVX-410, RAPA-201, RX-5902, SC10914, SCT200, SD-101, SG001, SHR2554, SHR7390, TPIV 110, TPIV 200, TQ-B3616, WOKVAC, ZEN-3694, anbenitamab, bemcentinib, AZD6738 (ceralasertib), eftilagimod alpha, eganelisib, grapiprant, ieramilimab, inCVAX, lacnotuzumab, ladiratuzumab vedotin, olinvacimab, pacmilimab, patritumab deruxtecan), AVB-620 (pegloprastide), peptide loaded dendritic cell immune peptidevaccine), CX-5461 (pidnarulex), plocabulin, praluzatamab ravtansine, LY3023414 (samotolisib), stenoparib, taminadenant, CB-839 (telaglenastat), eFT508 (tomivosertib), uliledlimab, uprosertib, varisacumab, INXN-1001 (veledimex), AZD2014 (vistusertib), xentuzumab, zelenoleucel, zenocutuzumab, efavirenz, endoxifen (en doxifen, capecitabine, cyclophosphamide, onapristone, tenalisib, taxane, serabelisib, epertinib, celetinib, cisplatin, vinblastine, 2X-111, KORTUC, LiPlaCis, ModraDoc006, Sarcodoxome, ixabepilone, zoledronic acid, anlotinib, niraparib, endostatin, enzalutamide, sacituzumab govitecan), Trilaciclib, Tegafur, uracil, tegafur, bicalutamide, fluzoparib, toripalimab, nivolumab, disitamabvedotin), alpelisib, apatinib, atezolizumab, avelumab, pegylated liposome doxorubicin, serplulimab, FCN-437c, GLSI-100, Hemay022, TAA013, TQB2450, OBI-822 (adagloxadsimolenin), SAR439859 (amcenestrant), POL6326 (balixafortide), buparlisib, AZD-9833 (camizestrant), AZD5363 (capivasertib), datopotamab deruxtecan), enobosarm, etirinotecan pegol, GDC-9545 (giredestrant), LY3484356 (imlunestrant), GDC-0077 (inavolisib), GDC-0068 (ipatasertib), G1T38 (lerociclib), NPS (nelipepimut-S), GDC-0032 (taselisib), birociclib, dimesna, entinostat, veliparib, elacestrant, EndoTAG-1, LY01005, NK105, Olaparib, mitoxantrone, eryaspase, bavituximab, ARX788, tezatabepmaltraxetan, testosterone, anastrozole, fruquintinib, durvalumab, binimetinib, pacritinib, pucotenlimab, dalpiciclib, KN046, bempegaldesleukin, galinpepimut-S, AMD-070 (mavorixafor), sapacitabine, BLEX404, CVA21, GEN1046, HS636, Nerofe, PDL1.t-haNK, PT-112, Teleukin, GSK2110183 (afuresertib), APG-2575 (lisaftoclax), PD0325901 (mirdametinib), oleclumab, VT-464 (seviteronel), EDO-S101 (tinostamustine), CDD-450 (zunsemetinib), bitinib, 111-In-ABY-025, 177Lu-NeoB, AK-01, AMXI-5001, ART4215, ARV-471, ATA2271, AZD8205, BEBT-209, BPI-1178, BPX-603, BT8009, BriaVax, CAM- H2, CFI-402257, ESG-401, FAZ053, GB1275, GEN1044, H3B-6545, HER2-CAR-T, IMGC936, NBE-002, NC76 2. NGM707, NKTR-262, NUV-422, OC-001, OMO-103, OP-1250, ORIN1001, REGN7075, RIVAL-01, S81694, SB T6050, SKB264, ST-067, TAEK-VAC, TAS0728, VX-803, ZN-c5, benufutamab, FP-1305 (bexmarilimab), eFT226, CAN04 (nadunolimab), triciribine phosphate, autologous tumor-infiltrating lymphocytes, recombinant human copper-zinc superoxide dismutase, and GLG-801.
7. Use according to claim 5 or 6, wherein the at least one additional active agent is a non-therapeutic agent.
8. The use according to claim 7, wherein the non-therapeutic agent is selected from the group consisting of antiemetics, antianemic drugs, antimucositis drugs, hypoglycemic drugs, hypolipidemic drugs, and antihypertensive drugs.
9. The use according to claim 8, wherein the non-therapeutic agent is selected from the group consisting of ondansetron, granisetron, dolasetron, palonosetron, metformin, simvastatin, lacidipine.
10. The use according to any one of the preceding claims, wherein According to pathological cytological classification, the breast cancer is selected from non-invasive cancer, invasive cancer, other rare cancers and combinations thereof.
11. The use according to claim 10, wherein The non-invasive cancer is selected from the group consisting of intraductal carcinoma, lobular carcinoma in situ, intraductal papillary carcinoma, eczematoid breast cancer of the nipple, and combinations thereof.
12. The use according to claim 10, wherein The invasive cancer is selected from invasive special cancer and / or invasive non-special cancer.
13. The use according to claim 12, wherein The invasive special carcinoma is selected from the group consisting of papillary carcinoma, medullary carcinoma, tubular carcinoma, adenoid cystic carcinoma, mucinous adenocarcinoma, apocrine carcinoma, squamous cell carcinoma, and combinations thereof.
14. The use according to claim 12, wherein The invasive non-special carcinoma is selected from the group consisting of invasive ductal carcinoma, invasive lobular carcinoma, scirrhous carcinoma, medullary carcinoma, simple carcinoma, adenocarcinoma, and combinations thereof.
15. The use according to any one of the preceding claims, wherein The cells involved in breast cancer are selected from one or more of the following: human breast cancer cell line MCF7, human breast cancer cell line T47D, and human breast cancer cell line BT474.
16. Use according to any one of the preceding claims, wherein The phosphorothioate antisense oligonucleotide targeting the IGF1R gene or the composition thereof is formulated as a lyophilized agent or an injection.
17. Use according to any one of the preceding claims, wherein The phosphorothioate antisense oligonucleotides targeting the IGF1R gene or compositions thereof are used in combination with one or more anti-cancer treatments, one or more cytostatic, cytotoxic or anti-cancer agents, targeted therapies, or a combination of any of the foregoing.
18. Use according to any one of the preceding claims, wherein The anti-cancer therapy is selected from the group consisting of chemotherapy, radiotherapy, biological therapy, bone marrow transplantation, and stem cell transplantation.
Citation Information
Patent Citations
Application of antisense oligonucleotide in preparation of medicine for treating kidney cancer
CN114306370A
